Opthea (NASDAQ:OPT – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Volatility & Risk Opthea has a beta of […]
Opthea (NASDAQ:OPT – Free Report) had its price target decreased by Oppenheimer from $31.00 to $16.00 in a report issued on Wednesday, MarketBeat reports. Oppenheimer currently has an outperform rating on the stock. Separately, HC Wainwright reiterated a buy rating and set a $14.00 target price on shares of Opthea in a research report on […]
HC Wainwright restated their buy rating on shares of Opthea (NASDAQ:OPT – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. Separately, EF Hutton Acquisition Co. I started coverage on Opthea in a report on Monday, April 17th. They set a […]
Opthea (NASDAQ:OPT – Free Report) and Angion Biomedica (NASDAQ:ANGN – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Opthea and Angion Biomedica’s […]
Opthea (NASDAQ:OPT – Get Rating) and Protalix BioTherapeutics (NYSE:PLX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Earnings & Valuation This table compares Opthea and Protalix BioTherapeutics’ […]